IOVANCE BIOTHERAPEUTICS, INC. Capital Expenditures Incurred but Not yet Paid
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Capital Expenditures Incurred but Not yet Paid of $683.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2024-05-09
- IOVANCE BIOTHERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2024-03-31 was $683.00K, a 91.22% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2023-12-31 was $310.00K, a 92.89% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2023-09-30 was -$61.00K, a 109.26% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2023-06-30 was -$3.96M.
- IOVANCE BIOTHERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2023 was $4.06M, a 32.13% decline from fiscal 2022.
- IOVANCE BIOTHERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2022 was $5.99M, a 51.77% decline from fiscal 2021.
- IOVANCE BIOTHERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2021 was $12.41M.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2024-03-31 | $683.00K 10-Q · filed 2024-05-09 | $993.00K derived: sum of 2 quarters · filed 2024-05-09 | $932.00K derived: sum of 3 quarters · filed 2024-05-09 | -$3.03M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | $310.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $249.00K derived: sum of 2 quarters · filed 2024-02-28 | -$3.71M derived: sum of 3 quarters · filed 2024-02-28 | $4.06M 10-K · filed 2024-02-28 |
| 2023-09-30 | -$61.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$4.03M derived: sum of 2 quarters · filed 2023-11-07 | $3.75M 10-Q · filed 2023-11-07 | $8.11M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-06-30 | -$3.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $3.81M 10-Q · filed 2023-08-08 | $8.17M derived: sum of 3 quarters · filed 2024-05-09 | $8.83M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-03-31 | $7.78M 10-Q · filed 2024-05-09 | $12.14M derived: sum of 2 quarters · filed 2024-05-09 | $12.79M derived: sum of 3 quarters · filed 2024-05-09 | $8.86M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $4.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $5.02M derived: sum of 2 quarters · filed 2024-02-28 | $1.08M derived: sum of 3 quarters · filed 2024-02-28 | $5.99M 10-K · filed 2024-02-28 |
| 2022-09-30 | $659.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$3.27M derived: sum of 2 quarters · filed 2023-11-07 | $1.63M 10-Q · filed 2023-11-07 | $8.31M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$3.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $967.00K 10-Q · filed 2023-08-08 | $7.65M derived: sum of 3 quarters · filed 2024-02-28 | $6.91M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $4.90M 10-Q · filed 2023-05-10 | $11.58M derived: sum of 2 quarters · filed 2024-02-28 | $10.84M derived: sum of 3 quarters · filed 2024-02-28 | $8.96M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $6.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $5.94M derived: sum of 2 quarters · filed 2024-02-28 | $4.06M derived: sum of 3 quarters · filed 2024-02-28 | $12.41M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$743.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$2.62M derived: sum of 2 quarters · filed 2022-11-03 | $5.73M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$1.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $6.47M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $8.35M 10-Q · filed 2022-05-05 | |||
| 2020-06-30 | $5.21M 10-Q · filed 2020-08-06 | |||
| 2019-06-30 | $92.00K 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |